Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

SuperGen discusses Orathecin rolling NDA submission plans with FDA

Aug. 22, 2003

Generex receives SBIR grant for HER-2/neu peptide vaccine for breast cancer

Aug. 21, 2003

New data on the molecular mechanisms underlying the antitumor activity of MS-275

Aug. 21, 2003

Japanese team presents new compounds with proapoptotic and cell adhesion-inhibitory activity

Aug. 20, 2003

Tumor necrosis therapy receives marketing approval for lung cancer in China

Aug. 20, 2003

CB-300638, a thmidylate synthase inhibitor with potential as an antitumor agent

Aug. 20, 2003

GTI-2040 cleared to enter NCI phase II breast cancer trial in combination with capecitabine

Aug. 19, 2003

SBIR grants support anticancer drug development at Tularik

Aug. 19, 2003

New, potent inhibitors of rat 17alpha-hydroxylase/C17,20-lyase

Aug. 18, 2003

FDA Advisory Committee schedules review of Metvix for basal cell carcinoma

Aug. 13, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...